Handelsavisen
prelaunch
Companies Healthcare RSCH.JK
RS
RSCH.JK IDX (Jakarta) Healthcare Facilities & Services

Charlie Hospital Semarang Tbk PT

$250,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-9,8 %
ROE
-12,6 %
Net margin
-14,4 %
Debt / equity
0,32
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Charlie Hospital Semarang Tbk PT operates in the healthcare facilities and services industry, providing medical services and pharmaceuticals to patients in Indonesia.

Business. Charlie Hospital Semarang Tbk PT (RSCH.JK) is a healthcare facilities and services company headquartered in Indonesia. The firm operates within the Healthcare Services & Equipment sector, providing medical services on a service-revenue basis. It is listed on the Indonesia Stock Exchange (IDX) under the ticker RSCH.JK. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-12,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning RSCH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to RSCH.JK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Charlie Hospital Semarang Tbk PT (RSCH.JK) is a healthcare facilities and services company headquartered in Indonesia. The firm operates within the Healthcare Services & Equipment sector, providing medical services on a service-revenue basis. It is listed on the Indonesia Stock Exchange (IDX) under the ticker RSCH.JK. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.32, indicating a relatively conservative leverage position. However, the liquidity risk is rated as medium, with a current ratio of 0.52, suggesting that the company may struggle to meet its short-term obligations. The negative operating cash flow of -6,193,955,460 IDR and free cash flow of -40,127,124,830 IDR further highlight the company's liquidity challenges.

    Profitability metrics are concerning, with a return on equity of -12.58% and a return on assets of -8.11%, both significantly below the industry median for healthcare facilities and services. The company reported a net loss of 16,420,240,770 IDR, and an operating loss of 11,249,588,050 IDR, indicating a need for operational improvements to align with industry standards.

    The company's revenue is concentrated in a single geographic region, as disclosed segments do not provide a breakdown of geographic exposure. This lack of diversification increases the company's vulnerability to regional economic or regulatory changes.

    The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The negative operating and free cash flows suggest a lack of momentum in revenue generation and operational efficiency.

    The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to fund operations without external financing. The dilution potential is low, with no significant adjustments applied to the valuation metrics.

    Recent events, as disclosed in the company's financial filings, include a significant capital expenditure of -43,573,533,770 IDR, which may indicate investments in infrastructure or expansion. However, the negative cash flows suggest that these investments have not yet translated into positive returns.

    Key takeaways
    • The company is operating at a loss, with a return on equity of -12.58% and a return on assets of -8.11%.
    • The liquidity risk is medium, with a current ratio of 0.52 and negative operating and free cash flows.
    • The company's revenue is concentrated in a single geographic region, increasing its vulnerability to regional economic or regulatory changes.
    • The capital structure is relatively conservative, with a debt-to-equity ratio of 0.32.
    • The company has a low dilution risk, but the negative net cash position after subtracting total debt could impact its ability to fund operations without external financing.
    • **margin_outlook_rationale**: The company's gross profit margin is 16.65%, but the negative operating and net income suggest a decline in profitability.
    • **rd_outlook_rationale**: No specific information is provided on research and development activities or their impact on future profitability.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $250,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $130.52B
    Net cash
    -$41.98B
    Current ratio
    0.5
    Debt / equity
    0.3
    ROA
    -8.1%
    ROE
    -12.6%
    Cash conversion
    38.0%
    CapEx / revenue
    -38.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-9,8 %Bottom quartile
    Net Margin-14,3 %Bottom quartile
    ROE-12,6 %Bottom quartile
    Capex / Rev-38,1 %Bottom quartile
    D/E0,32Above median
    Cash Conv0,38Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Charlie Hospital Semarang Tbk PT Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    RSCH.JKCanonical
    IDX (Jakarta) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage